References
1. Gnacińska M, Małgorzewicz S, Stojek M, Łysiak-Szydłowska W, Sworczak K. Adv Med Sci Role of adipokines in complications related to obesity: a review. 2009 (54):150-7.
2. Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula G. Joint Bone Spine Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. 2015 (82):187-91.
3. Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G. Autoimmun Rev Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. 2016 (15):447-50.
4. Budulgan M, Dilek B, Dağ ŞB, Batmaz I, Yıldız İ, Sarıyıldız MA,et al. . Clin Rheumatol Relationship between serum leptin level and disease activity in patients with systemic sclerosis. 2014 (33):335-9.
5. Winsz-Szczotka K, Kuźnik-Trocha K, Komosińska-Vassev K, Kucharz E, Kotulska A, Olczyk K. Int J Rheum Dis Relationship between adiponectin, leptin, IGF-1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. 2016 (19):706-14.
6. Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, et al. . Int J Rheum Dis Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. 2012 (15):374-9.
7. Korman BD, Marangoni RG, Hinchcliff M, Shah SJ, Carns M, Hoffmann A,et al. . Arthritis Rheumatol Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. 2017 (69):2062-8.
8. Michalska-Jakubus M, Sawicka K, Potembska E, Kowal M, Krasowska D. Postepy Dermatol Alergol Clinical associations of serum leptin and leptin/adiponectin ratio in systemic sclerosis. 2019 (36):325-38.
9. Tomčík M, Arima K, Hulejová H, Kuklová M, Filková M, Braun M,et al. . Cytokine Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. 2012 (58):165-8.
10. Żółkiewicz J, Stochmal A, Rudnicka L. Arch Dermatol Res The role of adipokines in systemic sclerosis: a missing link? 2019 (311):251-63.
11. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. . Arthritis Rheum 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. 2013 (65):2737-47.
12. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D’Angelo WA,et al. . J Rheumatol The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. 1998 (25):84-8.
13. LeRoy EC, Medsger TA. J Rheumatol Criteria for the classification of early systemic sclerosis. 2001 (28):1573-6.
14. Cutolo M, Matucci Cerinic M. Clin Exp Rheumatol Nailfold capillaroscopy and classification criteria for systemic sclerosis. 2007 (25):663-5.
15. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S, et al. . Ann Rheum Dis European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. 2001 (60):592-8.
16. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. . Arthritis Rheum Increased interleukin-17 production in patients with systemic sclerosis. 2000 (43):2455-63.
17. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F,et al. . Clin Exp Immunol Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. 2004 (138):540-6.
18. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. . Arthritis Res Ther Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. 2009 (11):R147.
19. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Clin Rheumatol Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. 2011 (30):231-7.
20. Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K,et al. . Exp Dermatol Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. 2011 (20):764-6.
21. Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML,et al. . Arthritis Res Ther Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? 2012 (14):R102. doi: 10.1186/ar3827.
22. Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N, et al. . Rheumatology (Oxford) A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. 2013 (52):1239-44.
23. Masui Y, Asano Y, Akamata K, Aozasa N, Noda S, Taniguchi T, et al. . Rheumatol Int Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis. 2014 (34):1165-70.
24. Neumann E, Lepper N, Vasile M, Riccieri V, Peters M, Meier F,et al. . Cytokine Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. 2019 (117):41-9.
25. Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U. Clin Rheumatol A decreased serum leptin level in patients with systemic sclerosis. 2001 (20):300-2.
26. Huertas A, Tu L, Gambaryan N, Girerd B, Perros F, Montani D,et al. . Eur Respir J Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. 2012 (40):895-904.
27. Komai AM, Brännmark C, Musovic S, Olofsson CS. J Physiol PKA-independent cAMP stimulation of white adipocyte exocytosis and adipokine secretion: modulations by Ca2+ and ATP. 2014 (592):5169-86.
28. Tilg H, Moschen AR. Clin Sci (Lond) Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. 2008 (114):275-88.
29. Masui Y, Asano Y, Shibata S, Noda S, Aozasa N, Akamata K, et al. . J Eur Acad Dermatol Venereol Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. 2012 (26):354-60.
30. Zapata-Gonzalez F, Auguet T, Aragonès G, Guiu-Jurado E, Berlanga A, Martinez S, et al. . Int J Mol Sci Interleukin-17A Gene Expression in Morbidly Obese Women. 2015 (16):17469-81.
31. Dorneles GP, Haddad DO, Fagundes VO, Vargas BK, Kloecker A, Romão PR, et al. . Cytokine High intensity interval exercise decreases IL-8 and enhances the immunomodulatory cytokine interleukin-10 in lean and overweight-obese individuals. 2016 (77):1-9.
32. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. J Rheumatol Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. 1997 (24):663-5.
33. Distler JH, Jordan S, Airo P, Alegre-Sancho JJ, Allanore Y, Balbir Gurman A, et al. . Clin Exp Rheumatol Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. 2011 (29):S40-5.
34. Bishop V, Harrison E, Lal S, Herrick AL. Scand J Rheumatol Evidence for a clinical association between body mass index and malabsorption in patients with systemic sclerosis. 2015 (44):341-3.
35. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J,et al. . Nature Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. 1985 (316):552-4.
36. Mahony SM, Beck SA, Tisdale MJ. Br J Cancer Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour. 1988 (57):385-9.
37. Chen CY, Tsai CY, Lee PC, Lee SD. Curr Pharm Des Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptin. 2013 (19):1956-64.
Table 1. Clinical findings of Systemic Sclerosis (SSc) cohort (n. 89 patients).